Overview

Efficacy and Safety Study of ZK219477 in Patients With Recurrent Ovarian Cancer

Status:
Completed
Trial end date:
2007-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if this epothilone leads to a response in patients with recurrent ovarian cancer that has progressed during, or in the last six months since a treatment of platinum-based chemotherapy. We also aim to look at the safety of the study drug and assess the impact of the infusion duration on tolerability.
Phase:
Phase 2
Details
Lead Sponsor:
Bayer
Treatments:
Epothilones
Sagopilone